All In Biotech

Drug Trial Radar · NCT05505916

An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)

An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900, an Oral Plasma Kallikrein Inhibitor, for On-demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema Type I or II

Last checked: Nov 19, 2026Latest source record: Jun 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

145

Actual

Start

Oct 24, 2022

Primary completion

May 27, 2026

Study completion May 27, 2026

Sponsor

Lead sponsor
KalVista Pharmaceuticals, Ltd.Industry
Sponsor type
Industry
First posted
Aug 18, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, multicenter extension trial to evaluate the long-term safety of KVD900 in patients who are 12 years or older with HAE type I or II.

Conditions

  • Hereditary Angioedema

Interventions

  • KVD900 600 mgDrug

    KVD900 Tablet 600 mg (2 x 300 mg)

  • KVD900 300 mgDrug

    KVD900 Tablet 300 mg

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Frequencies and percentages of patients with AEs, AEs within 2 days of IMP administration, serious AE's and AEs causing premature discontinuation.Time frame: AEs will be recorded from the first dose of IMP in the KVD900-302 trial up to and including the end of study (EOS) visit, a maximum of 2 years for each patient.
  2. Number and percentage of patients with normal or abnormal laboratory results at each scheduled visit.Time frame: Throughout the duration of the trial.
  3. Number and percentage of patients with normal or abnormal vital sign results at each scheduled visitTime frame: Throughout the duration of the trial.

Locations

71 sites in 23 countries. Site status is shown where the registry gives one.

  • KalVista Investigative Site

    Scottsdale, Arizona

  • KalVista Investigative Site

    Little Rock, Arkansas

  • KalVista Investigative Site

    San Diego, California

  • KalVista Investigative Site

    San Diego, California

  • KalVista Investigative Site

    Santa Monica, California

  • KalVista Investigative Site

    Centennial, Colorado

  • KalVista Investigative Site

    Colorado Springs, Colorado

  • KalVista Investigative Site

    Evansville, Indiana

  • KalVista Investigative Site

    Overland Park, Kansas

  • KalVista Investigative Site

    Louisville, Kentucky

  • KalVista Investigative Site

    Chevy Chase, Maryland

  • KalVista Investigative Site

    Plymouth, Minnesota

  • KalVista Investigative Site

    St Louis, Missouri

  • KalVista Investigative Site

    Charlotte, North Carolina

  • KalVista Investigative Site

    Cincinnati, Ohio

  • KalVista Investigative Site

    Toledo, Ohio

  • KalVista Investigative Site

    Hershey, Pennsylvania

  • KalVista Investigative Site

    Dallas, Texas

  • KalVista Investgative Site

    Layton, Utah

  • KalVista Investigative Site

    Spokane, Washington

  • KalVista Investigative Site

    Campbelltown, Australia

  • KalVista Investigative Site

    Wein, Austria

  • KalVista Investigative Site

    Sofia, Bulgaria

  • KalVista Investigative Site

    Montreal, Canada

  • KalVista Investigative Site

    Grenoble, France

  • KalVista Investigative Site

    Lille, France

  • KalVista Investigative Site

    Paris, France

  • KalVista Investigative Site

    Berlin, Germany

  • KalVista Investigative Site

    Frankfurt, Germany

  • KalVista Investigative Site

    Mainz, Germany

  • KalVista Investigative Site

    Mörfelden-Walldorf, Germany

  • KalVista Investigative Site

    Athens, Greece

  • KalVista Investigative Site

    Athens, Greece

  • KalVista Investigative Site

    Budapest, Hungary

  • KalVista Investigative Site

    Haifa, Israel

  • KalVista Investigative Site

    Petach Tikvah, Israel

  • KalVista Investigative Site

    Ramat Gan, Israel

  • KalVista Investigative Site

    Tel Aviv, Israel

  • KalVista Investigative Site

    Padova, Italy

  • KalVista Investigative Site

    Palermo, Italy

Showing 40 of 71 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.